Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Rating of “Reduce” by Brokerages

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received a consensus rating of “Reduce” from the six brokerages that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $16.20.

A number of analysts have weighed in on the stock. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $11.00 to $16.00 in a research report on Thursday, May 28th. Finally, Wells Fargo & Company boosted their target price on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently made changes to their positions in IART. Osaic Holdings Inc. raised its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares during the period. State of Tennessee Department of Treasury boosted its stake in Integra LifeSciences by 7.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after buying an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares in the last quarter. Capital Fund Management S.A. lifted its position in Integra LifeSciences by 5.7% in the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after buying an additional 1,997 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in Integra LifeSciences in the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

IART remained flat at $18.05 during trading on Friday. 682,936 shares of the company’s stock traded hands, compared to its average volume of 920,119. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $18.92. The firm has a market cap of $1.40 billion, a P/E ratio of -2.79, a price-to-earnings-growth ratio of 1.25 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The business’s fifty day moving average is $15.57 and its 200 day moving average is $12.68.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same period last year, the firm posted $0.41 earnings per share. Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.